期刊文献+

中国5所医院念珠菌属对氟康唑和伏立康唑的耐药性监测 被引量:47

Surveillance of resistance to fluconazole and voriconazole in Candida isolates from 5 hospitals in China
下载PDF
导出
摘要 目的了解临床分离念珠菌属和其他酵母对氟康唑和伏立康唑的耐药性及耐药性变迁。方法按CLSI/NCCLS M44-A推荐的纸片扩散法对2001年至2005年8 000株念珠菌属和其他酵母临床分离株进行氟康唑和伏立康唑的药敏试验;并通过BIOMIC软件换算出相应的MIC(mg/L)。结果白念珠菌及非白念珠菌如光滑念珠菌等在临床分离真菌中的分布自2001—2005年未见有明显的上升趋势。2001—2005年白念珠菌对氟康唑和伏立康唑的耐药率变化不大,但光滑念珠菌等非白念珠菌对氟康唑和伏立康唑的耐药率有不同程度的上升。结论伏立康唑较氟康唑具有更广的抗菌谱和更强的抗菌活性;光滑念珠菌等非白念珠菌的耐药率正在逐年上升;提示对念珠菌属开展耐药性监测的重要性。 Objective To investigate the situation and change of antifungal resistance in clinical Candida and other fungal isolates from 5 hospitals in diverse geographic region of China. Methods Antimicrobial susceptibility testing of 8 000 fungal isolates collected during 2001 and 2005 were carried out with 25 μg fluconazole disk and 1 μg voriconazole disk using disk diffusion method as recommend by CLSI/NCCLS M44-A. Disk test plates were automatically read and results were recoded with the BIOMIC Image Analysis System. The equivalent MICs were automatically calculated by the BIOMIC System software. Results The proportion of Candida albicans and non-Candida albicans (e. g. Candida glabrata) in the total fungal isolates did not change significantly from 2001 to 2005. The susceptibility rate of C. albicans to fluconazole and voriconazole were stable during 2001 and 2005. However, the resistance to fluconazole and voriconazole increased variably in C. glabrata and other non- Candida albicans fungal isolates during the same period. Conclusions The voriconazole demonstrated higher activity against all yeast species in comparison with fluconazole. The increasing resistance to fluconazole and voriconazole in non C. albicans fungal isolates including C. glabrata suggests the importance of surveillance of fungal resistance in Candida isolates.
出处 《中国感染与化疗杂志》 CAS 2007年第1期14-18,共5页 Chinese Journal of Infection and Chemotherapy
关键词 真菌耐药性监测 抗真菌药 真菌药敏试验 Surveillance of fungal resistance Antifungal agent Fungal susceptibility testing
  • 相关文献

参考文献10

  • 1Groll AH,Shah PM,Mentzel C,et al.Trends in the postmorten epidemiology of invosive fungal infections at a university hospital[J].J Infect,1996,33(1):23-32.
  • 2Beck-Sague C,Jarvis WR.Secular trends in the epidemiology of nosocomial fungal infections in the United States,1980-1990.National Nosocomial Surveillance System[J].J Infect Dis,1993,167(5):1247-1251.
  • 3江丽华,翁香琴.1999—2001年丽水市中心医院重症监护病房真菌耐药性分析[J].中国抗感染化疗杂志,2003,3(3):157-158. 被引量:6
  • 4周竹超,倪泉兴,吴菊芳,章强强.普外科真菌感染84例临床调查[J].中国抗感染化疗杂志,2004,4(4):219-222. 被引量:11
  • 5National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing;Ninth Supplement to the M2-A8,M100-S14[s].January 2004,NCCLS,Villanova,PA.
  • 6Wenzel R,Brewer TF,Butzle JP,et al.A guide to infection diseases.Boston,MA.USA,BC Decker Inc Hamiltom.London,2002:157-159.
  • 7Hazen KC,Baron EJ,Colombo AL,et al.Comparison of susceptibilities of Candida spp.to fluconazole and voriconazole in a 4-year global evalution using disk diffusion[J].J Clin Microbiol,2003,41(12):5623-5632.
  • 8Pfaller MA,Diekema DJ,Rinaldi MG,et al.Results from the ARTEMIS DISK Global Antifungal Surveillance Study:a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing[J].J Clin Microbiol,2005,43(12):5848-5859.
  • 9Pfaller MA,Boyken L,Messer A,et al.Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program[J].J Clin Microbiol.2005,43(10):5208-5213.
  • 10Pfaller MA,Diekema DJ,Rex JH,et al.Correlation of MIC with outcome for Candida species tested against voriconazole:analysis and proposal for interpretive breakpoints[J].J Clin Microbiol,2006,44(3):819-826.

二级参考文献10

共引文献14

同被引文献296

引证文献47

二级引证文献348

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部